Compositions and methods for producing antibody-generating immune organoids
AssigneeParallel Biosystems, Inc.
InventorsRobert M. DIFAZIO, Juliana L. HILLIARD
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the generation of antibody-producing, three dimensional, immune organoids. The disclosure also provides methods useful for producing such immune organoids.
Claims46
A three dimensional immune organoid comprising a plurality of self-assembled primary immune cells obtained from one or more secondary lymphoid organs and a plurality of stem cells, wherein said stem cells are CD34+, CD45RA−, ITGA3+, EPCR+, CD90+, CD73+, and CD105+.
The immune organoid of any preceding claim, wherein the immune organoid is a human immune organoid.
The immune organoid of any preceding claim, further comprising peripheral blood mononuclear cells.
The immune organoid of any preceding claim, wherein the plurality of immune cells is obtained from living patients, surgical resections, fine needle aspirates, biopsy, and deceased patients.
The immune organoid of any preceding claim, wherein the plurality of immune cells comprises B cells, T cells, plasmablasts, NK cells, monocytes, dendritic cells, macrophages and combinations thereof.
The immune organoid of any preceding claim, wherein the plurality of primary immune cells further comprises one or more stromal cells and fibroblastic reticular cells.
The immune organoid of any preceding claim, wherein the immune organoid is 8000 μm or less in diameter.
The immune organoid of any preceding claim, wherein the immune organoid comprises germinal centers and/or B/T cell zones.
The immune organoid of any preceding claim, wherein the immune organoid produces antibodies.
A composition comprising:
- a plurality of primary immune cells of which 100% self-assemble into 3 dimensional immune organoids within 24 hours.
A method of producing multiple three dimensional immune organoids, the method comprising:
- (a) dissociating tissue from one or more secondary lymphoid organs to produce a plurality of single primary immune cells;
- (b) contacting 1×106 or fewer of the plurality of single primary immune cells with a solid support;
- and
- (c) culturing the plurality of single primary immune cells for 24 hours to produce multiple three dimensional immune organoids, wherein the multiple immune organoids remain viable for at least 30 days.
Dependencies are inferred from the claim text.